Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R-CVAD) alternating with high-dose methotrexate and cytarabine (AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for those who reached only a partial response. After a median follow-up of 10·5 years, we reported 10-year progression-free and overall survival rates of 35% and 61% respectively, with a 10-years cumulative incidence rate of second malignancies of 10·6%. Mature results of the MCL01 trial confirmed the efficacy of HyperCVAD-AM as a frontline regimen for younger patients (≤65 years).
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma / Massaro, F.; Stepanishyna, Y.; Manni, M.; Luminari, S.; Galimberti, S.; Marcheselli, L.; Visco, C.; Tecchio, C.; Stelitano, C.; Angrilli, F.; Petrini, M.; Merli, F.; Federico, M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - (2020), pp. 1-4.
Data di pubblicazione: | 2020 |
Titolo: | Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma |
Autore/i: | Massaro, F.; Stepanishyna, Y.; Manni, M.; Luminari, S.; Galimberti, S.; Marcheselli, L.; Visco, C.; Tecchio, C.; Stelitano, C.; Angrilli, F.; Petrini, M.; Merli, F.; Federico, M. |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1111/bjh.16714 |
Rivista: | |
Pagina iniziale: | 1 |
Pagina finale: | 4 |
Codice identificativo ISI: | WOS:000532665700001 |
Codice identificativo Scopus: | 2-s2.0-85084468598 |
Codice identificativo Pubmed: | 32410259 |
Citazione: | Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma / Massaro, F.; Stepanishyna, Y.; Manni, M.; Luminari, S.; Galimberti, S.; Marcheselli, L.; Visco, C.; Tecchio, C.; Stelitano, C.; Angrilli, F.; Petrini, M.; Merli, F.; Federico, M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - (2020), pp. 1-4. |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
471.pdf | Versione dell'editore (versione pubblicata) | Administrator Richiedi una copia |

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris